Chronic Myeloid Leukemia with a Rare Philadelphia Chromosome Variant Involving Chromosome 16

被引:0
作者
Bahashwan, Salem M. [1 ,2 ]
机构
[1] King Abdulaziz Univ, Fac Med, Dept Hematol, Jeddah, Saudi Arabia
[2] King Abdulaziz Univ, King Fahd Med Res Ctr, Hematol Res Unit, Jeddah, Saudi Arabia
关键词
Imatinib Mesylate; Karyotyping; Leukemia; Myelogenous; Chronic; BCR-ABL Positive; Philadelphia Chromosome; FRONTLINE IMATINIB THERAPY; GIMEMA WORKING PARTY; PROGNOSTIC INFLUENCE; RANDOMIZED CML; TRANSLOCATIONS; DIAGNOSIS; IMPACT;
D O I
10.12659/AJCR.944641
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Rare coexistence of disease or pathology Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the presence of the Philadelphia (Ph) chromosome, which results from the fusion of the translocation of the ABL1 gene from chromosome 9 to the BCR gene located in chromosome 22, forming the BCR-ABL gene on chromosome number 22, which accounts for approximately 95% of CML cases. Complex translocation involving other chromosomes can occur. Case Report: We present a rare case of CML with a variant Ph chromosome, in which chromosome 16 was involved with the usual translocation. A 34-year-old woman presented with a history of left upper quadrant pain and excessive sweating, with no hepatosplenomegaly on examination. She was found to have leukocytosis, with elevated neutrophils (34 000/mm3), 3 ), basophils (1460/mm3), 3 ), and eosinophils (2650/mm3). 3 ). Karyotyping showed a translocation (16;22) (q24,q11.2), and FISH analysis showed BCR-ABL fusion as a result of (9,22) translocation, with a third chromosome (chromosome 16) involved and fused with chromosome 22, with a different breakpoint, which has never been reported in the literature, affecting the long arm of chromosome 16. The patient was treated with a first-generation tyrosine kinase inhibitor (imatinib) and achieved a deep molecular remission. The repeated FISH analysis confirmed the disappearance of both translocations (9,22) and (16,22). Conclusions: The impact of the additional chromosomal aberration in CML is widely heterogeneous, and the outcome is dependent on multiple factors. Larger studies are needed to clarify the outcome in CML with variant Ph chromosomes, as most of the available data come from reported cases.
引用
收藏
页数:5
相关论文
共 22 条
  • [1] Fluorescence in situ hybridization: a highly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias
    Amare, PS
    Baisane, C
    Saikia, T
    Nair, R
    Gawade, H
    Advani, S
    [J]. CANCER GENETICS AND CYTOGENETICS, 2001, 131 (02) : 125 - 134
  • [2] Asif M, 2017, BIOMED REP, V7, P377, DOI 10.3892/br.2017.967
  • [3] Complex karyotype with a masked Philadelphia translocation and variant BCR-ABL fusion in CML
    Bakshi, Sonal R.
    Patel, Beena P.
    Brahmbhatt, Manisha M.
    Trivedi, Pina J.
    Gajjar, Sarju B.
    Iyer, Ramesh R.
    Parikh, Esha H.
    Shukla, Shilin N.
    Shah, Pankaj M.
    [J]. CANCER GENETICS AND CYTOGENETICS, 2009, 189 (02) : 142 - 143
  • [4] Chauffaille M.de L.L. F., 2011, Blood, V118, P4903, DOI DOI 10.1182/BLOOD.V118.21.4903
  • [5] Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase
    Choi, Eun-Ji
    [J]. BLOOD RESEARCH, 2023, 58 : 29 - 36
  • [6] Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome
    El-Zimaity, MMT
    Kantarjian, H
    Talpaz, M
    O'Brien, S
    Giles, F
    Garcia-Manero, G
    Verstovsek, S
    Thomas, D
    Ferrajoli, A
    Hayes, K
    Bekele, BN
    Zhou, X
    Rios, MB
    Glassman, AB
    Cortes, JE
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (02) : 187 - 195
  • [7] A complex translocation (9;22;16)(q34;q11.2;p13) in chronic myelocytic leukemia
    Espinoza, JPM
    Cárdenas, VJP
    Jiménez, EAV
    Angulo, MG
    Flores, MAE
    García, JRG
    [J]. CANCER GENETICS AND CYTOGENETICS, 2005, 157 (02) : 175 - 177
  • [8] The Impact of Variant Philadelphia Chromosome Translocations on the Clinical Course of Chronic Myeloid Leukemia
    Eyupoglu, Damla
    Bozkurt, Sureyya
    Haznedaroglu, Ibrahim
    Buyukasik, Yahya
    Guven, Deniz
    [J]. TURKISH JOURNAL OF HEMATOLOGY, 2016, 33 (01) : 60 - 65
  • [9] Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
    Fabarius, Alice
    Leitner, Armin
    Hochhaus, Andreas
    Mueller, Martin C.
    Hanfstein, Benjamin
    Haferlach, Claudia
    Goehring, Gudrun
    Schlegelberger, Brigitte
    Jotterand, Martine
    Reiter, Andreas
    Jung-Munkwitz, Susanne
    Proetel, Ulrike
    Schwaab, Juliana
    Hofmann, Wolf-Karsten
    Schubert, Joerg
    Einsele, Hermann
    Ho, Anthony D.
    Falge, Christiane
    Kanz, Lothar
    Neubauer, Andreas
    Kneba, Michael
    Stegelmann, Frank
    Pfreundschuh, Michael
    Waller, Cornelius F.
    Spiekermann, Karsten
    Baerlocher, Gabriela M.
    Lauseker, Michael
    Pfirrmann, Markus
    Hasford, Joerg
    Saussele, Susanne
    Hehlmann, Ruediger
    [J]. BLOOD, 2011, 118 (26) : 6760 - 6768
  • [10] Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
    Hasford, Joerg
    Baccarani, Michele
    Hoffmann, Verena
    Guilhot, Joelle
    Saussele, Susanne
    Rosti, Gianantonio
    Guilhot, Francois
    Porkka, Kimmo
    Ossenkoppele, Gert
    Lindoerfer, Doris
    Simonsson, Bengt
    Pfirrmann, Markus
    Hehlmann, Rudiger
    [J]. BLOOD, 2011, 118 (03) : 686 - 692